(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are China SXT Pharmaceuticals, Aspen Group, and Seanergy Maritime Holdings Corp.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | China SXT Pharmaceuticals (SXTC) | 0.15 | 19.44% | 2023-09-19 13:15:07 |
| 2 | Aspen Group (ASPU) | 0.15 | 16.73% | 2023-09-19 12:16:21 |
| 3 | Seanergy Maritime Holdings Corp (SHIPW) | 0.03 | 10% | 2023-09-19 05:14:06 |
| 4 | Repare Therapeutics (RPTX) | 11.20 | 8.53% | 2023-09-19 01:44:06 |
| 5 | Scholar Rock Holding Corporation (SRRK) | 6.71 | 7.53% | 2023-09-19 11:09:08 |
| 6 | Virgin Galactic (SPCE) | 2.00 | 6.68% | 2023-09-19 13:01:49 |
| 7 | MicroVision (MVIS) | 2.26 | 6.09% | 2023-09-19 13:14:08 |
| 8 | iRobot (IRBT) | 37.37 | 5.3% | 2023-09-19 13:13:33 |
| 9 | Lumen Technologies (LUMN) | 1.60 | 5.26% | 2023-09-19 13:02:18 |
| 10 | Scienjoy Holding Corporation (SJ) | 2.88 | 5.11% | 2023-09-19 07:12:06 |
The three biggest losers today are Synlogic, Nio, and Ebix.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Synlogic (SYBX) | 0.34 | -16.65% | 2023-09-19 13:23:07 |
| 2 | Nio (NIO) | 8.81 | -14.56% | 2023-09-19 12:58:00 |
| 3 | Ebix (EBIX) | 11.40 | -13% | 2023-09-19 13:12:09 |
| 4 | TRACON Pharmaceuticals (TCON) | 0.23 | -8.74% | 2023-09-19 15:13:07 |
| 5 | SG Blocks (SGBX) | 1.39 | -8.55% | 2023-09-19 05:10:07 |
| 6 | Rumble (RUM) | 5.46 | -7.93% | 2023-09-19 13:24:16 |
| 7 | Sol-Gel Technologies Ltd. (SLGL) | 2.27 | -7.72% | 2023-09-19 07:14:06 |
| 8 | SELLAS Life Sciences Group (SLS) | 1.50 | -6.83% | 2023-09-19 07:23:07 |
| 9 | Sunrun (RUN) | 14.10 | -6.37% | 2023-09-19 03:10:07 |
| 10 | So-Young International (SY) | 1.03 | -5.91% | 2023-09-19 13:17:07 |
Winners today
1. China SXT Pharmaceuticals (SXTC) – 19.44%
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. It offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. The company provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of July 31, 2021, its end-customer base includes 70 pharmaceutical companies, 12 chain pharmacies, and 59 hospitals in 10 provinces and municipalities in China, including Jiangsu, Hubei, Shandong, Guangdong, Liaoning, Anhui, Henan, Jiangxi, Heilongjiang, and Hainan. The company was founded in 2005 and is based in Taizhou, China.
NASDAQ ended the session with China SXT Pharmaceuticals jumping 19.44% to $0.15 on Tuesday, following the last session’s downward trend. NASDAQ slid 0.23% to $13,678.19, following the last session’s upward trend on what was a somewhat bearish trend exchanging session today.
Earnings Per Share
As for profitability, China SXT Pharmaceuticals has a trailing twelve months EPS of $-0.88.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.15%.
Moving Average
China SXT Pharmaceuticals’s worth is below its 50-day moving average of $0.17 and way below its 200-day moving average of $0.32.
More news about China SXT Pharmaceuticals.
2. Aspen Group (ASPU) – 16.73%
Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.
NASDAQ ended the session with Aspen Group jumping 16.73% to $0.15 on Tuesday while NASDAQ fell 0.23% to $13,678.19.
Earnings Per Share
As for profitability, Aspen Group has a trailing twelve months EPS of $-0.39.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.
More news about Aspen Group.
3. Seanergy Maritime Holdings Corp (SHIPW) – 10%
NASDAQ ended the session with Seanergy Maritime Holdings Corp jumping 10% to $0.03 on Tuesday, after five sequential sessions in a row of losses. NASDAQ dropped 0.23% to $13,678.19, following the last session’s upward trend on what was a somewhat negative trend trading session today.
PE Ratio
Seanergy Maritime Holdings Corp has a trailing twelve months price to earnings ratio of 0.21. Meaning, the purchaser of the share is investing $0.21 for every dollar of annual earnings.
Yearly Top and Bottom Value
Seanergy Maritime Holdings Corp’s stock is valued at $0.03 at 17:32 EST, under its 52-week high of $0.03 and higher than its 52-week low of $0.03.
More news about Seanergy Maritime Holdings Corp.
4. Repare Therapeutics (RPTX) – 8.53%
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
NASDAQ ended the session with Repare Therapeutics jumping 8.53% to $11.20 on Tuesday while NASDAQ dropped 0.23% to $13,678.19.
Earnings Per Share
As for profitability, Repare Therapeutics has a trailing twelve months EPS of $-0.06.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1.31%.
More news about Repare Therapeutics.
5. Scholar Rock Holding Corporation (SRRK) – 7.53%
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
NASDAQ ended the session with Scholar Rock Holding Corporation jumping 7.53% to $6.71 on Tuesday, following the last session’s downward trend. NASDAQ slid 0.23% to $13,678.19, following the last session’s upward trend on what was a somewhat negative trend trading session today.
Earnings Per Share
As for profitability, Scholar Rock Holding Corporation has a trailing twelve months EPS of $-1.92.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -60.1%.
Volume
Today’s last reported volume for Scholar Rock Holding Corporation is 87070 which is 78.25% below its average volume of 400441.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 5.5% and a drop 15.2% for the next.
Moving Average
Scholar Rock Holding Corporation’s value is above its 50-day moving average of $6.65 and way below its 200-day moving average of $8.17.
More news about Scholar Rock Holding Corporation.
6. Virgin Galactic (SPCE) – 6.68%
Virgin Galactic Holdings, Inc. focuses on the development, manufacture, and operation of spaceships and related technologies for conducting commercial human spaceflight and flying commercial research and development payloads into space. It is also involved in the ground and flight testing, and post-flight maintenance of its spaceflight system vehicles. The company serves private individuals, researchers, and government agencies. Virgin Galactic Holdings, Inc. was founded in 2017 is headquartered in Las Cruces, New Mexico.
NYSE ended the session with Virgin Galactic rising 6.68% to $2.00 on Tuesday while NYSE fell 0.15% to $15,929.01.
Earnings Per Share
As for profitability, Virgin Galactic has a trailing twelve months EPS of $-2.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -101.26%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Virgin Galactic’s stock is considered to be oversold (<=20).
Volume
Today’s last reported volume for Virgin Galactic is 8224810 which is 64.18% below its average volume of 22965200.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Virgin Galactic’s EBITDA is -4.24.
Volatility
Virgin Galactic’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.04%, a negative 1.90%, and a positive 4.66%.
Virgin Galactic’s highest amplitude of average volatility was 4.85% (last week), 3.46% (last month), and 4.66% (last quarter).
More news about Virgin Galactic.
7. MicroVision (MVIS) – 6.09%
MicroVision, Inc. develops and sells lidar sensors used in automotive safety and autonomous driving applications. Its laser beam scanning technology is based on micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company also develops micro-display concepts and designs for head-mounted augmented reality (AR) headsets, as well as 1440i MEMS module supporting AR headsets; interactive display solutions for the smart speakers market; and Consumer Lidar used in smart home systems. In addition, it develops 1st Generation LRL module. The company sells its products primarily to original equipment manufacturers and original design manufacturers. MicroVision, Inc. was founded in 1993 and is headquartered in Redmond, Washington.
NASDAQ ended the session with MicroVision jumping 6.09% to $2.26 on Tuesday, after two successive sessions in a row of losses. NASDAQ dropped 0.23% to $13,678.19, following the last session’s upward trend on what was a somewhat negative trend trading session today.
Earnings Per Share
As for profitability, MicroVision has a trailing twelve months EPS of $-0.38.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -63.85%.
More news about MicroVision.
8. iRobot (IRBT) – 5.3%
iRobot Corporation designs, builds, and sells robots and home innovation products in the United States, Europe, the Middle East, Africa, Japan, and internationally. The company offers floor care products, including Roomba floor vacuuming robots; Roomba accessories and consumables, such as the Clean Base Automatic Dirt Disposal, replacement dirt disposal bags for the Clean Base, filters, brushes, and batteries; Braava family of automatic floor mopping robots; and Braava accessories and consumables, which include cleaning solution, washable and disposable mopping pads, replacement tanks, and batteries, as well as subscription services. It also provides H1 Handheld Vacuum, a portable vacuum; H1 Handheld Vacuum accessories comprising filters, chargers, batteries, and an extension kit that converts the H1 Handheld Vacuum into a stick vacuum; air purifiers under the Aeris brand; Root robots to help children learn how to code; and Create 3, a mobile robot platform that offers an opportunity for educators, developers, and high-school and college students to program behaviors, sounds, movements, and add additional electronics, as well as sells filters and fabric covers. The company sells its products through chain stores and other national retailers, distributors, and resellers, as well as through its website and app, and e-commerce websites. iRobot Corporation was incorporated in 1990 and is headquartered in Bedford, Massachusetts.
NASDAQ ended the session with iRobot jumping 5.3% to $37.37 on Tuesday, following the last session’s upward trend. NASDAQ dropped 0.23% to $13,678.19, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, iRobot has a trailing twelve months EPS of $-13.75.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -74.71%.
Volume
Today’s last reported volume for iRobot is 189370 which is 52.12% below its average volume of 395561.
Sales Growth
iRobot’s sales growth is negative 11.9% for the ongoing quarter and negative 16.2% for the next.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, iRobot’s stock is considered to be overbought (>=80).
Yearly Top and Bottom Value
iRobot’s stock is valued at $37.37 at 17:32 EST, way below its 52-week high of $58.93 and way above its 52-week low of $31.37.
More news about iRobot.
9. Lumen Technologies (LUMN) – 5.26%
Lumen Technologies, Inc., a facilities-based technology and communications company, provides various integrated products and services under the Lumen, Quantum Fiber, and CenturyLink brands to business and residential customers in the United States and internationally. The company operates in two segments, Business and Mass Markets. It offers compute and application services, such as edge cloud services, IT solutions, unified communication and collaboration solutions, colocation and data center services, content delivery services, and managed security services; and IP and data services, including VPN data network, Ethernet, internet protocol (IP), and voice over internet protocol. The company also provides fiber infrastructure services comprising high bandwidth optical wavelength networks; and unlit optical fiber and related professional services. In addition, it offers voice and other services, including private line services, a direct circuit or channel specifically dedicated for connecting two or more organizational sites; a portfolio of traditional time division multiplexing voice services; and synchronous optical network-based ethernet, legacy data hosting services, and conferencing services. The company was formerly known as CenturyLink, Inc. and changed its name to Lumen Technologies, Inc. in September 2020. The company was incorporated in 1968 and is headquartered in Monroe, Louisiana.
NYSE ended the session with Lumen Technologies rising 5.26% to $1.60 on Tuesday, after two consecutive sessions in a row of losses. NYSE dropped 0.15% to $15,929.01, after two successive sessions in a row of losses, on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, Lumen Technologies has a trailing twelve months EPS of $-11.36.
Volume
Today’s last reported volume for Lumen Technologies is 8380720 which is 60.82% below its average volume of 21391900.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Lumen Technologies’s stock is considered to be oversold (<=20).
More news about Lumen Technologies.
10. Scienjoy Holding Corporation (SJ) – 5.11%
Scienjoy Holding Corporation provides mobile live streaming platforms in the People's Republic of China. It focuses on interactive show live streaming from broadcasters to users. The company's platforms enable users to view and interact with broadcasters through online chat, virtual items, and playing games. As of December 31, 2021, it had 840,640 paying users and 288,898 active broadcasters. The company operates four live streaming platforms under the Showself Live Streaming, Lehai Live Streaming, Haixiu Live Streaming, BeeLive Live Stream names. It also offers technical development and advisory services. The company was founded in 2011 and is based in Beijing, the People's Republic of China. Scienjoy Holding Corporation is a subsidiary of Lavacano Holdings Limited.
NASDAQ ended the session with Scienjoy Holding Corporation jumping 5.11% to $2.88 on Tuesday, following the last session’s upward trend. NASDAQ fell 0.23% to $13,678.19, following the last session’s upward trend on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, Scienjoy Holding Corporation has a trailing twelve months EPS of $0.41.
PE Ratio
Scienjoy Holding Corporation has a trailing twelve months price to earnings ratio of 7.02. Meaning, the purchaser of the share is investing $7.02 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.48%.
Yearly Top and Bottom Value
Scienjoy Holding Corporation’s stock is valued at $2.88 at 17:32 EST, way below its 52-week high of $4.80 and way above its 52-week low of $1.25.
Revenue Growth
Year-on-year quarterly revenue growth declined by 28.3%, now sitting on 1.65B for the twelve trailing months.
Volume
Today’s last reported volume for Scienjoy Holding Corporation is 41337 which is 112.66% above its average volume of 19438.
More news about Scienjoy Holding Corporation.
Losers Today
1. Synlogic (SYBX) – -16.65%
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
NASDAQ ended the session with Synlogic sliding 16.65% to $0.34 on Tuesday, after three consecutive sessions in a row of gains. NASDAQ slid 0.23% to $13,678.19, following the last session’s upward trend on what was a somewhat bearish trend exchanging session today.
Earnings Per Share
As for profitability, Synlogic has a trailing twelve months EPS of $-1.38.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -75.85%.
Moving Average
Synlogic’s value is way under its 50-day moving average of $0.48 and way below its 200-day moving average of $0.63.
Revenue Growth
Year-on-year quarterly revenue growth declined by 77%, now sitting on 993k for the twelve trailing months.
Volume
Today’s last reported volume for Synlogic is 103931 which is 50% below its average volume of 207893.
More news about Synlogic.
2. Nio (NIO) – -14.56%
NIO Inc. designs, develops, manufactures, and sells smart electric vehicles in China. It offers five and six-seater electric SUVs, as well as smart electric sedans. The company also offers power solutions, including Power Home, a home charging solution; Power Swap, a battery swapping service; Power Charger and Destination Charger; Power Mobile, a mobile charging service through charging vans; Power Map, an application that provides access to a network of public chargers and their real-time information; and One Click for Power valet service. In addition, it provides repair, maintenance, and bodywork services through its NIO service centers and authorized third-party service centers; statutory and third-party liability insurance, and vehicle damage insurance through third-party insurers; repair and routine maintenance; courtesy vehicle services; roadside assistance; data packages; and auto financing and financial leasing services. Further, the company involved in the provision of energy and service packages to its users; design and technology development activities; manufacture of e-powertrains, battery packs, and components; and sales and after sales management activities. Additionally, it offers NIO Certified, a used vehicle inspection, evaluation, acquisition, and sales service. The company was formerly known as NextEV Inc. and changed its name to NIO Inc. in July 2017. NIO Inc. was incorporated in 2014 and is headquartered in Shanghai, China.
NYSE ended the session with Nio falling 14.56% to $8.81 on Tuesday while NYSE slid 0.15% to $15,929.01.
Nio stock forecast: $1 billion convertible senior notes send NIO shares tumblingBased on the Nio stock price action, it is safe to assume the market thinks most of these notes will be converted into American Depositary Shares (ADSs), thus diluting existing shareholders., At the end of the second quarter, Nio had approximately $3.9 billion in debt - about 20% higher than six months prior.
Earnings Per Share
As for profitability, Nio has a trailing twelve months EPS of $-1.73.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -77.63%.
Volatility
Nio’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.47%, a negative 0.12%, and a positive 3.47%.
Nio’s highest amplitude of average volatility was 2.84% (last week), 2.49% (last month), and 3.47% (last quarter).
Earnings Before Interest, Taxes, Depreciation, and Amortization
Nio’s EBITDA is 0.4.
More news about Nio.
3. Ebix (EBIX) – -13%
Ebix, Inc., together with its subsidiaries, provides on-demand infrastructure software exchanges and e-commerce services to the insurance, financial, travel, cash remittance, and healthcare industries in the United States and internationally. The company develops and deploys insurance and reinsurance exchanges on an on-demand basis using software-as-a-service (SaaS) enterprise solutions in the areas of customer relationship management, front-end and back-end systems, and outsourced administrative and risk compliance solutions. Its EbixCash exchange related products and services include gift cards; travel exchanges services; money transfer services; foreign exchange and outward remittance services; consumer payment services; and on-demand technology to various providers in the areas of lending, wealth and asset management, and travel. The company's insurance exchanges related products and services include SaaS platform and related services; licensing of software; and professional services comprising setup, customization, training, or consulting. Its risk compliance services cover certificates of insurance creation and tracking; consulting services, such as project management, integration, development, and testing; and business process outsourcing services, including domain intensive project management, system consulting services, and claims adjudication/settlement services. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Johns Creek, Georgia.
NASDAQ ended the session with Ebix dropping 13% to $11.40 on Tuesday while NASDAQ dropped 0.23% to $13,678.19.
Earnings Per Share
As for profitability, Ebix has a trailing twelve months EPS of $1.09.
PE Ratio
Ebix has a trailing twelve months price to earnings ratio of 10.46. Meaning, the purchaser of the share is investing $10.46 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.64%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Ebix’s stock is considered to be oversold (<=20).
Sales Growth
Ebix’s sales growth is negative 40% for the present quarter and negative 49.3% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Ebix’s EBITDA is 1.14.
More news about Ebix.
4. TRACON Pharmaceuticals (TCON) – -8.74%
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
NASDAQ ended the session with TRACON Pharmaceuticals dropping 8.74% to $0.23 on Tuesday, after two successive sessions in a row of gains. NASDAQ slid 0.23% to $13,678.19, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, TRACON Pharmaceuticals has a trailing twelve months EPS of $-1.17.
Earnings Before Interest, Taxes, Depreciation, and Amortization
TRACON Pharmaceuticals’s EBITDA is 0.05.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 66.7% and 51.6%, respectively.
More news about TRACON Pharmaceuticals.
5. SG Blocks (SGBX) – -8.55%
SG Blocks, Inc. designs and modifies code-engineered cargo shipping containers and purpose-built modules for commercial, industrial, and residential building construction in the United States. The company redesigns, repurposes, and convert heavy-gauge steel cargo shipping containers into SGBlocks, which are green building blocks for construction. It serves architects, landowners, builders, and developers. SG Blocks, Inc. was founded in 2007 and is headquartered in Jacksonville, Florida.
NASDAQ ended the session with SG Blocks falling 8.55% to $1.39 on Tuesday while NASDAQ slid 0.23% to $13,678.19.
Earnings Per Share
As for profitability, SG Blocks has a trailing twelve months EPS of $-1.27.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -105.41%.
Yearly Top and Bottom Value
SG Blocks’s stock is valued at $1.39 at 17:32 EST, way below its 52-week high of $2.10 and way above its 52-week low of $0.74.
Revenue Growth
Year-on-year quarterly revenue growth declined by 32.5%, now sitting on 18.84M for the twelve trailing months.
More news about SG Blocks.
6. Rumble (RUM) – -7.93%
Rumble Inc. operates video sharing platforms in the United States, Canada, and internationally. The company operates rumble.com, a platform where users can subscribe to channels to stay in touch with creators, and access video on-demand (VOD) and live content streamed by creators. It also operates locals.com, a subscription platform for creators and subscribers to engage through VOD, podcasts, live chat, polls, and community discussions; and Rumble Advertising Center (RAC), an online advertising management exchange. The company was founded in 2013 and is headquartered in Longboat Key, Florida.
NASDAQ ended the session with Rumble dropping 7.93% to $5.46 on Tuesday, after five sequential sessions in a row of losses. NASDAQ dropped 0.23% to $13,678.19, following the last session’s upward trend on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, Rumble has a trailing twelve months EPS of $-0.28.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -35.81%.
Sales Growth
Rumble’s sales growth is 131.1% for the ongoing quarter and 50% for the next.
Yearly Top and Bottom Value
Rumble’s stock is valued at $5.46 at 17:32 EST, under its 52-week low of $5.81.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Rumble’s stock is considered to be overbought (>=80).
More news about Rumble.
7. Sol-Gel Technologies Ltd. (SLGL) – -7.72%
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
NASDAQ ended the session with Sol-Gel Technologies Ltd. dropping 7.72% to $2.27 on Tuesday while NASDAQ dropped 0.23% to $13,678.19.
Earnings Per Share
As for profitability, Sol-Gel Technologies Ltd. has a trailing twelve months EPS of $-1.04.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -52.48%.
More news about Sol-Gel Technologies Ltd..
8. SELLAS Life Sciences Group (SLS) – -6.83%
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
NASDAQ ended the session with SELLAS Life Sciences Group falling 6.83% to $1.50 on Tuesday while NASDAQ fell 0.23% to $13,678.19.
Earnings Per Share
As for profitability, SELLAS Life Sciences Group has a trailing twelve months EPS of $-1.6.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -301.92%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 108.8% and 37.2%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SELLAS Life Sciences Group ‘s EBITDA is 20.84.
Volume
Today’s last reported volume for SELLAS Life Sciences Group is 116103 which is 7.82% below its average volume of 125957.
More news about SELLAS Life Sciences Group .
9. Sunrun (RUN) – -6.37%
Sunrun Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. It also sells solar energy systems and products, such as panels and racking; and solar leads generated to customers. In addition, the company offers battery storage along with solar energy systems. Its primary customers are residential homeowners. The company markets and sells its products through direct-to-consumer approach across online, retail, mass media, digital media, canvassing, field marketing, and referral channels, as well as its partner network. Sunrun Inc. was founded in 2007 and is headquartered in San Francisco, California.
NASDAQ ended the session with Sunrun dropping 6.37% to $14.10 on Tuesday, after two sequential sessions in a row of losses. NASDAQ dropped 0.23% to $13,678.19, following the last session’s upward trend on what was a somewhat down trend trading session today.
Earnings Per Share
As for profitability, Sunrun has a trailing twelve months EPS of $0.38.
PE Ratio
Sunrun has a trailing twelve months price to earnings ratio of 37.11. Meaning, the purchaser of the share is investing $37.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -14.49%.
Volume
Today’s last reported volume for Sunrun is 8058590 which is 11.45% below its average volume of 9100930.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 109.4% and a negative 127.6%, respectively.
Sales Growth
Sunrun’s sales growth is negative 8.1% for the current quarter and negative 1.4% for the next.
Yearly Top and Bottom Value
Sunrun’s stock is valued at $14.10 at 17:32 EST, way below its 52-week high of $37.20 and higher than its 52-week low of $13.30.
More news about Sunrun.
10. So-Young International (SY) – -5.91%
So-Young International Inc. operates an online platform for medical aesthetics and consumption healthcare services focusing on discretionary medical treatments. Its platform enables users to discover content and share their own experience on medical aesthetics procedures and leads users to reserve treatment services from medical aesthetic service providers for offline treatment in the People's Republic of China and internationally. The company facilitates research on medical aesthetic treatment trends; ratings and reviews on treatment experiences; and blogs under the name Beauty Diaries. It also provides reservation services in the areas of dermatology, dentistry and orthodontics, ophthalmology, physical examinations, gynecology, human papilloma virus vaccines, and postnatal care; Software as a Service; and guiding and consulting services through training programs for medical service providers. In addition, the company offers internet information and technology advisory, management consulting, and Internet culture services, as well as sells medical equipment. As of December 31, 2020, it had approximately 6,900 medical aesthetic service providers and 4,200 other consumption healthcare service providers on its platform. The company was founded in 2013 and is headquartered in Beijing, China.So-Young International Inc. operates an online platform for medical aesthetics and consumption healthcare services focusing on discretionary medical treatments. Its platform enables users to discover content and share their own experience on medical aesthetics procedures and leads users to reserve treatment services from medical aesthetic service providers for offline treatment in the People's Republic of China and internationally. The company facilitates research on medical aesthetic treatment trends; ratings and reviews on treatment experiences; and blogs under the name Beauty Diaries. It also provides reservation services in the areas of dermatology, dentistry and orthodontics, ophthalmology, physical examinations, gynecology, human papilloma virus vaccines, and postnatal care; Software as a Service; and guiding and consulting services through training programs for medical service providers. In addition, the company offers internet information and technology advisory, management consulting, and Internet culture services, as well as sells medical equipment. As of December 31, 2020, it had approximately 6,900 medical aesthetic service providers and 4,200 other consumption healthcare service providers on its platform. The company was founded in 2013 and is headquartered in Beijing, China.
NASDAQ ended the session with So-Young International dropping 5.91% to $1.03 on Tuesday, following the last session’s downward trend. NASDAQ slid 0.23% to $13,678.19, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, So-Young International has a trailing twelve months EPS of $0.02.
PE Ratio
So-Young International has a trailing twelve months price to earnings ratio of 51.75. Meaning, the purchaser of the share is investing $51.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.84%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 33.3%, now sitting on 1.37B for the twelve trailing months.
Sales Growth
So-Young International’s sales growth is 15% for the present quarter and 21.5% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
So-Young International’s EBITDA is -0.07.
Yearly Top and Bottom Value
So-Young International’s stock is valued at $1.03 at 17:32 EST, way under its 52-week high of $3.07 and way above its 52-week low of $0.50.
More news about So-Young International.
Stay up to date with our winners and losers daily report
